Category: 2 or 3L

  • Novartis’ Canakinumab Fails to Meet its Primary Endpoint in P-III CANOPY-2 Study

    Shots: The P-III CANOPY-2 study involves assessing canakinumab (ACZ885) + CT (docetaxel) in 237 adults with LA/m-NSCLC, prior treatment with PD-L1 inhibitors and Pt-based CT. The study did not meet its 1EPs of OS The company will continue to evaluate the therapy in ongoing P-III CANOPY-1 and CANOPY-A studies evaluating canakinumab in 1L and adjuvant […]